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Available online 7 October 2016Bisphosphonates have established their role as medical therapy for pediatric osteogenesis imperfecta (OI) pa-
tients. Since bisphosphonates have also been shown to delay tooth development in animal models, we aimed
to assess whether the medication has a similar effect on children with OI. In this cross-sectional study, bisphos-
phonate-treated OI patients of whom dental panoramic tomograph was taken between 3 and 16 years of age
formed the study group. The patients, 22 in total, had been treated with pamidronate, zoledronic acid or
risedronate for at least one year before the radiography. Developmental stage of the permanent teeth, resorption
of the deciduous teeth, and number of the erupted permanent teeth were radiographically assessed in the left
mandibular quadrant. Dental panoramic tomographs of 50 OI patients, naïve to bisphosphonates, and of 50
healthy individuals of the same age were used as controls. The dental development was statistically signiﬁcantly
accelerated in the OI group naïve to bisphosphonates showing median advancement of dental age by 0.63 years
from chronological age and median increase in the number of erupted teeth by 0.31 as compared to Finnish
norms. Bisphosphonate-treated OI patients displayed, however, age-appropriate dental development. The OI pa-
tients not treated with bisphosphonates also showed statistically signiﬁcantly faster resorption of the deciduous
teeth than the treated ones, and displayed an altered interrelationship between the resorption stage of an indi-
vidual primary tooth and the developmental stage of the succedaneous permanent tooth, unlike the OI patients
treated with bisphosphonate. No correlation between either cumulative bisphosphonate dose or between treat-
ment length and any measured component of the dental development was found. To conclude, OI itself was
found to lead to advanced dental development. Bisphosphonate treatment had a delaying effect in all the three
aspects studied, resulting in a rate of dental development indistinguishable from normal.






Osteogenesis imperfecta (OI) is an inherited disorder characterized
by bone fragility and skeletal deformities [1]. In the great majority of
the cases, OI is caused by a mutation in one of the two genes encoding
type I collagen (COL1A1, COL1A2). During the past years, mutations in
several other genes have also been identiﬁed to cause OI. These genes
code for proteins that take part in the posttranslational modiﬁcation
of type I collagen, folding, and osteoblast development [2].etics, P.O. Box 63, University ofIn addition to skeletal features, the typical manifestations of OI in-
clude blue sclerae, hearing loss, excess joint laxity, growth deﬁciency,
and bone pain. Dental anomalies, such as structural abnormality of den-
tin and hypodontia, are also prevalent. In fact, only 22% of the patients
with OI have been reported not to have any detectable dental abnormal-
ities [3]. Malocclusion is alsomuchmore frequent and severe in patients
with OI than in their unaffected peers [4].
Bisphosphonates have established their role asmedical treatment of
pediatric OI patients and are generally well tolerated. Their mainmech-
anism of action is inhibition of osteoclast function and bone resorption.
Eruption of any tooth requires resorption of the alveolar bone, and in
question of permanent teeth other than molars, also resorption of the
roots of the pre-existing primary teeth. Since osteoclasts are responsible
for the resorption of both, bisphosphonate treatment can be anticipated
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treated with zoledronic acid or alendronate [5–7]. There are also data
suggesting that locally administered ibandronate retards orthodontic
tooth movement in rabbits [8]. Evidence for similar effects in humans
is sparse, only one study showing a reduced number of clinically
erupted teeth in bisphosphonate-treated patients with OI in compari-
son to healthy children [9].
The purpose of the present study was to examine if the timing of
dental development in children with OI differs from normal, and to ob-
tain information on the effect of therapeutic doses of bisphosphonates
on the timing of human dental development. We analyzed the dental
development from three aspects: 1) development of the permanent
teeth 2) resorption of the primary teeth, and 3) eruption of the perma-
nent teeth. The study subjects were children with OI who had received
bisphosphonate treatment. To control the effect of bisphosphonates
separately from OI itself, we compared the ﬁndings with two types of
controls: 1) a historical group of children with OI whowere not treated
with bisphosphonates, and 2) a group of healthy children of the same
ethnicity.
2. Subjects and methods
2.1. Study subjects
The study group comprised children and adolescents with OI,
treated at the Children's Hospital, Helsinki University Hospital. The
patients were eligible for inclusion if they were aged between 3
and 16 years, and if they had been treated with bisphosphonates
for a minimum period of one year. The upper age limit was set at
16 years, before anticipated completion of dental development,
third molars excluded. Altogether 39 patients (24 boys, 15 girls) ful-
ﬁlled these criteria and they were contacted by mail and phone. Of
them, 17 (9 boys, 8 girls) gave a written informed consent to partic-
ipation in clinical evaluation and radiography; one of them was not
able to follow the study protocol because of current health problems
and was excluded from the ﬁnal data analyses. The study patients
were examined by a dentist (H.A.) in 2013, and a dental panoramic
tomograph (DPT) was obtained if one was not available from the
previous 3 years (12 patients). In addition, DPTs, taken within 3
years, were available for 6 patients (4 boys and 2 girls) who did not
take part in the clinical evaluation, and these were included in the
analysis.
The ﬁnal study group thus comprised 22 patients (13 boys, 9 girls)
from 20 families. The type of OI was classiﬁed according to Sillence
et al. [10]. Of the patients 16 had type I, ﬁve type III, and one type
IV OI. Presence of dentinal abnormality, often referred as type I
dentinogenesis imperfecta, was assessed using clinical and radio-
graphic criteria [11].
All patients in the study grouphadbeen treatedwith at least one bis-
phosphonate preparation and for more than one year at the time of the
radiography. The used bisphosphonates were intravenous pamidronate
and zoledronic acid as well as orally administered risedronate. The dos-
ing was 9 mg/kg/year, divided in 3–6 three-day infusion cyclesTable 1
Description of the study group. Results are given as median (range).
OI type I





Age at the time of imaging (y) 10.2 (4.8–15.7)
Age at treatment onset (y) 6.4 (1.2–13.0)
Time from treatment onset (y) 4.7 (1.1–8.3)
Cumulative BP dosea 2000 (900–5250)
a Cumulative bisphosphonate dose was calculated as (total dose received [mg]/weight [kg])
bisphosphonate.depending on the age, for pamidronate, and 0.05 mg/kg every six
months for zoledronic acid. The risedronate oral dose was 2.5 mg daily
for patients who weighted 10–30 kg and 5 mg/day for patients who
weighted over 30 kg. All medication data were collected from clinical
records to calculate the cumulative dose per body weight, expressed
as mg/kg. Because of the differing molecules, we used coefﬁcients also
to sum up the cumulative doses of different bisphosphonates. The coef-
ﬁcients were based on relative potencies of the molecules to in vitro in-
hibit bone resorption. They were 100 for pamidronate, 10,000 for
zoledronic acid, and 2000 for risedronate [12]. The bioavailability of
orally administered risedronate (0.63%) was also taken into account
(Table 1).
The non-participants (n = 17) did not differ signiﬁcantly from the
study group by gender, age or OI type (p N 0.05). The reasons for non-
participation were lack of interest, lack of time, and long distance to
study center.
2.2. Control groups
A historical OI control group comprised 50 childrenwithOI of whom
DPT had been taken (Table 2). They were born between 1966 and 2002
in 48 families living in Finland. Of them 47 had not received
bisphosphonates because their use in the treatment of OI did not start
before 2000 in Finland. Of these children 30 had type I, eight type III,
and nine type IV OI. Three boys with type I OI, born between 1990 and
2002, had not received the medication because diagnosis of OI had not
beenmade before the time of the radiography or because of a mild phe-
notype. Data for two OI control patients were also included in the OI
study group after the onset of their bisphosphonate treatment.
Another control group comprised randomly chosen 50 healthy chil-
dren from the records of Helsinki Longitudinal Growth Study at the In-
stitute of Dentistry, University of Helsinki [13]. From the series of DPTs
taken on all participating children for analysis of normal childhood
and adolescence growth and craniofacial development, we used DPTs
that had been taken at ages ranging from 4.6 to 13.6 years (Table 2).
The study protocol was approved by the Research Ethics Committee,
Children's Hospital, Helsinki University Hospital, and the Ethics Com-
mittee of the Institute of Dentistry, University of Helsinki. The study
conﬁrms to STROBE (STrengthening the Reporting of OBservational
studies in Epidemiology) guidelines.
2.3. Radiographic analyses
All radiographic analyses were performed using DPTs. The radio-
graphs of the study group were analyzed together by authors I.V. and
H.A. The radiographs of the OI control group and healthy controls
were evaluated by H.A. Blinding was not possible since most of the
study group's DPTs were recent and in digital format, whereas the
vast majority DPTs of untreated OI patients as well as all of the healthy
controls were in ﬁlm format. Moreover, blinding between the historical
OI group and group of healthy controls was not undertaken since they
were radiologically distinguishable by the dentinal abnormality, fre-






10.1 (3.9–14.3) 10.2 (3.9–15.7)
2.1 (0.1–11.8) 6.2 (0.1–13.0)
4.8 (1.3–10.2) 4.7 (1.1–10.2)
2900 (1500–6750) 2000 (900–6750)
multiplied by the relative potency of the medication. OI, osteogenesis imperfecta; BP,
Table 2
Description of the control groups. Results are given as median (range). OI, osteogenesis imperfecta.
OI controls
Healthy controlsOI type I OI type III & IV Total











Age at the time of imaging (y) 7.5 (3.9–15.6) 7.2 (3.1–13.7) 7.4 (3.0–15.6) 8.6 (4.6–13.6)
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duced by [14] and weighted norms for Finnish boys and girls [15]. The
method determines dental age by evaluating the radiographic appear-
ance of seven permanent left mandibular teeth, supplemented by the
corresponding right side tooth if one of the index teeth was missing or
could not be evaluated for any reason. In short, based on the progression
of the mineralization of each index tooth, the method recognizes eight
stages (A–H) where A corresponds to mineralization of the cusp tips
and Hmarks a fully developed tooth. The dental development was con-
sidered notably delayed or advanced if it differed from the chronological
age by more than twelve months.
The stage of resorption of primary teeth was assessed based on a
method described by Haavikko [16]. We analyzed the ﬁve primary
teeth in the left mandibular quadrant, and modiﬁed the method into a
simpler form inwhich the stage of resorption was divided into four cat-
egories by the length of the root, and each toothwas scored accordingly:
1= full root present, 2 = a quarter of the root resorbed, 3= half of the
root resorbed, and 4= the root completely resorbed (Fig. 1). If a prima-
ry tooth had already exfoliated, it was scored as 4. The scores were
summed up to form a resorption sum score, ranging from 5 to 20.
The two analyses above were combined to assess the relationship
between the resorption stage of an individual primary tooth and the de-
velopmental stage of the succedaneous permanent tooth.
Radiographic assessment of the permanent tooth eruption, deﬁned
as alveolar eruption, also included the left mandibular teeth. A tooth
was considered emerged if it had pierced the alveolar bone cortex,
whether or not it had pierced the oral mucosa. As reference values we
used published norms for timing of tooth eruption in healthy Finnish
children [13]. The timing of tooth eruption was considered abnormal
if outside the 5th or 95th percentile.
2.4. Statistical analyses
We assessed the intra-examiner error between duplicated evalua-
tions of dental age using Dahlberg's formula. The intra-examiner error
was 0.34 years which is 3.1% of the mean corresponding measurement.
Thus, we considered the intra-examiner error acceptable. Wilcoxon
rank-sum test was used to evaluate the difference between the chrono-
logical age and the calculated dental age within both OI groups, andFig. 1. Resorption stages of primary teeth. Resorption stages from left to right: A) full root
present, B) a quarter of the root resorbed, C) half of the root resorbed, D) the root
completely resorbed. The developing permanent premolars are seen under the primary
molars and represent here Demirjian stages D in (A), E in (C), and F in (B, D). Thus, the
developmental stage of the permanent tooth and the resorption stage of the above-lying
primary tooth are not completely inter-related.Mann-Whitney-U test to evaluate the differences between the groups.
Wilcoxon rank-sum test was also used to test if the number of erupted
permanent teeth in the OI groups differed from reported normal values.
Mann-Whitney-U test was again used to evaluate the differences be-
tween the groups. Analysis of variance (ANOVA) was applied, using
age as a covariate, to compare the stage of primary tooth root resorption
between the groups. Spearman's correlation coefﬁcient was used to de-
termine the correlation between relative cumulative dose or duration of
bisphosphonate treatment and above-mentioned outcome variables. p
values b0.05were considered statistically signiﬁcant. Statistical calcula-
tions were carried out using SPSS software for Windows (version 22;
SPSS Inc., Chicago, IL, USA).
3. Results
In the study group of 22 bisphosphonate-treated childrenwith OI,
the median difference between the patient's dental age and chrono-
logical age was +0.20 years (−1.49–+3.89, SD 1.26), and the differ-
ence was statistically non-signiﬁcant (p = 0.23). In the OI control
group of 50 children that had not received bisphosphonates the den-
tal development was, however, accelerated − the median advance-
ment was 0.63 years (−2.03–+3.77, SD 1.24), and the difference
between dental and chronological age was statistically signiﬁcant
(p b 0.001). The two OI groups did not, however, differ from each
other statistically signiﬁcantly (p = 0.21) with respect to the accel-
eration of dental development.
The resorption sum scores for primary teethwere statistically signif-
icantly different between the three groups when age was used as a co-
variate (p = 0.042). The resorption was faster in the OI patients not
treated with bisphosphonates than in the treated ones (p = 0.036).
The difference was, however, statistically non-signiﬁcant when either
treated or untreated patients were compared to healthy controls
(p= 0.23 and p= 0.62, respectively).
In the bisphosphonate-treated OI patients and healthy controls root
resorption in the primary tooth never began until the crown of the un-
derlying permanent tooth was complete (Demirjian stage D), whereas
the resorption started earlier in 27% of the teeth in the historical OI
group that had not received bisphosphonates (Fig. 2).
As amarker of permanent tooth eruptionwe counted the number of
left mandibular permanent teeth that had radiographically pierced the
alveolar bone. When this number in the bisphosphonate-treated OI
group was compared to age-appropriate Finnish norms [13], the aver-
age difference was 0.05 (−2–+2, SD 0.18, p=0.80) and hence statisti-
cally non-signiﬁcant. The number of erupted teeth was, however,
signiﬁcantly higher in the untreated OI subjects than in the Finnish
norms, the difference being 0.31 (−3–+3, SD 0.97, p = 0.029). The
two OI groups did not differ signiﬁcantly from each other (p = 0.23).
The tooth count was above the 95th percentile of age-dependent refer-
ence values in 2 patients (9.0%) in the OI study group and 5 patients
(10.0%) in the OI control group but it was not markedly low in any of
the patients in either group.
The acceleration within dental age and eruption of permanent teeth
seemed to be even more pronounced in the subgroup of OI patients
with dentinal abnormality (Table 3). The differences between the sub-
groups of OI patients with and without dentinal abnormality were,
however, non-signiﬁcant (p = 0.19 and p = 0.08, respectively). The
Fig. 2. Relationship between Demirjian stage of the permanent tooth and resorption stage of the deciduous tooth above it. For instance, when the permanent tooth had reached stage F
(root higher than crown) the primary tooth above could show any stage of resorption from full root left to completely resorbed in all subject groups analyzed, but the resorption was
more advanced in the OI patients who had not received bisphosphonates than in those who had been treated with bisphosphonates. Permanent teeth representing Demirjian stage A
(initiation of the mineralization) were few and were left out from the graph.
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affect the rate of resorption of primary teeth.
The median time elapsed from the onset of bisphosphonate treat-
ment to the time of radiographywas 4.7 years (1.1–10.2). Neither treat-
ment time nor relative cumulative dose correlated with the rate of
dental development, resorption of primary teeth or eruption of perma-
nent teeth (p N 0.05).
4. Discussion
Our study revealed that OI patients, naïve to bisphosphonates, have
on average advanced dental development. As compared to healthy
peers they showed acceleration in both dental age and eruption of the
permanent teeth. Against this background, we were able to show, in
line with our expectations and observations in animal studies, that
bisphosphonates slow down dental development in humans as well,
and as a new ﬁnding, we also demonstrate statistically signiﬁcant
delay in the resorption of primary teeth. Clinically importantly, howev-
er, the overall delay due to bisphosphonates is likely to rescue the accel-
erated dental development in patients with OI to a level comparable to
unaffected children.
The results conﬁrm our long-term clinical impression that especially
in childrenwithmore severe types of OI it used to be common in the era
before bisphophonate treatment to see relatively early shedding of the
primary teeth and replacement by permanent incisors, canines and pre-
molars as well as eruption of the permanent molars particularly in the
lower jaw. Children with OI often need extensive and complicated den-
tal care, such as protection of teeth with abnormal dentin with stainless
steel crowns or orthodontic treatment. Such treatments are easier to
perform in amoremature, co-operative child, and therefore early dental
development can be considered a disadvantage.
This observation on statistically signiﬁcantly advanced dental devel-
opment in OI is new and has not been reported in the very few previous
studies focusing on dental development in OI. Malmgren and Norgren
[3] reported that in 1 out of 68 patients the clinical tooth eruption was
delayed, and the deviant observation concerned a child in primary
tooth stage. Of their patients 32 were 5–14 year-olds and none ofTable 3
Results when all subjects with osteogenesis imperfecta were subgrouped according to bisphos
n Difference between dental and chronological ages (y) p-Value
BP+/DI− 17 +0.37 (−1.49–+3.89) 0.47
BP+/DI+ 5 +0.43 (−1.17–+1.46) 0.35
BP−/DI− 31 +0.58 (−2.03–+3.77) b0.01
BP−/DI+ 19 +0.93 (−1.43–+3.77) b0.01
Total/DI 48 +0.51 (−2.03–+3.89) 0.01
Total/DI+ 24 +0.82 (−1.43–+3.77) 0.04them exhibited abnormal timing of tooth eruption as compared to pub-
lished population norms. O'Connel and Marini [17] reported that in 40
children, with either type III or IV OI, clinical tooth eruption was within
normal range for both the primary and permanent teeth for most pa-
tients. They similarly applied Demirjian method [14] to assess dental
age in a subset of 27 children for whom DPTs could be obtained, ending
up with a result that in 5 patients the dental age was accelerated and in
4 patients delayed by N12 months compared to the chronological age.
To the best of our knowledge there is only one published study con-
sidering the effect of bisphosphonates on dental development in pa-
tients with OI, published by Kamoun-Goldrat et al. [9]. The study
setting was notably different from ours in that only unaffected children
were used as controls and that the assessment of dental age was based
on the number of emerged permanent teeth, as evaluated by visual in-
spection. Since the tooth count was statistically signiﬁcantly lower in
the bisphosphonate-treated children with OI than in the matched
healthy controls, the authors concluded that bisphosphonates lead to
delayed eruption of permanent teeth. Yet, in lack of radiographic data,
numbers were not corrected for congenitally missing or impacted
teeth. The prevalence of hypodontia in patients with OI is about 20%
[18], and impaction of particularly the upper second permanent molars
is frequent due to lack of space and bulbous crowns [3]. Thus the calcu-
lated dental age in subjects with OI was most probably markedly
underestimated.
During tooth eruption osteoclasts resorb the above-lying alveolar
bone while osteoblasts form new bone at the base of the tooth, causing
thereby an intra-osseousmovement of the tooth towards the oral cavity
[19], and the dental follicle has a decisive role in induction and regula-
tion of these cells [20]. The importance of the role of these two cell
types for dental eruption is of particular interest in patients with OI, be-
cause both osteoclastic and osteoblastic activities are characteristically
accelerated in the disorder [21]. We suggest that the accelerated bone
turnover might be the reason for the advanced development and erup-
tion of permanent teeth in medically unmodiﬁed OI.
The suppressed activity of osteoclasts by bisphosphonates probably
affects tooth development in a diverse pattern. Indeed, our study
showed no general difference between the rate of development of thephonate (BP) treatment and dentinal abnormality (DI). Results are given as mean (range).
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healthy individuals. Thus it seemed that bisphosphonate treatment at
least at these therapeutic doses normalized the otherwise accelerated
tooth development in children with OI. Nevertheless, bisphosphonates
have other medical indications in pediatrics, such as glucocorticoid-in-
duced juvenile osteoporosis [22], and a bisphosphonate-induced delay
in dental development in patient groups other than OI is a concern. In
an experimental mouse study, high doses of zoledronic acid, mimicking
its potential therapeutic use in children and adolescents with osteosar-
coma, impaired tooth development and eruption severely and irrevers-
ibly [23]. All in all, the severity of adverse effects on tooth development
and eruption are likely to be dose-dependent and particularly harmful
to the teeth with ongoing root formation at the time of the delivery of
the medication. Third molars included, this would indicate that all pa-
tients under the age of 23 [24], with current or previous bisphosphonate
treatment, should be followedup clinically and radiographically by den-
tal specialists.
The resorption of the roots of the primary teeth is a crucial part of
eruption of most permanent teeth as well. The cells responsible for
that are osteoclasts, as with bone [25], and the control of these cells is
mostly similar to the cells resorbingbone. For instance, RANKL (receptor
activator of nuclear kappa B ligand) and osteoprotegerin (OPG) have
similar effects on both osteoclast groups [26]. In contrast, parathyroid
hormone affects the resorption of teeth and bone differently. It has
been hypothesized that thedifference is rather caused by cementoblasts
covering the root and preventing osteoclastic resorption of the root [27].
Here we demonstrated a delaying effect of bisphosphonates on the re-
sorption of primary teeth, indicating similar effects on both groups of
osteoclasts. The effect of bisphosphonate on tooth resorption has not
been evaluated in animal studies and the delayed resorption is therefore
a completely new ﬁnding, albeit not unexpected. Clinically, an un-or-
chestrated primary tooth resorption aggravates the effect of delayed
permanent tooth development and is likely to increase the need of pri-
mary tooth extractions and follow-up of tooth eruption and occlusal
development.
The limitations of this study include the fact that this is an uncon-
trolled cross-sectional study and the control groups consist of historical
patients and healthy subjects. Differences other thanmedical treatment
may therefore exist in the clinical management of the OI groups. The
groups were also not identical. The impact of age was minimized
using reference values, and using age as a co-variant only when essen-
tial. The lack of blinding of the investigators to the subjects' agewas con-
sidered to have little effect on the analysis outcome aswas shownby the
results of the method error calculation. The fairly small number of pa-
tients did not allowus to statistically compare the effects of the different
bisphophonate preparations or types of OI. The statistical analyzes were
hallmarked by notable inter-individual variation in the timing of dental
development in both OI groups. Further studies with larger populations
and from a longitudinal aspect are likely to show whether a delay in
dental development in some individuals will reach clinical signiﬁcance
and whether one developmental stage more than the other is sensitive
to the delaying effects of the medication.
In conclusion, the present study shows that children with OI are on
average advanced in terms of dental development. It also shows that
bisphosphonate treatment delays dental development in patients with
OI. As a net effect, bisphosphonate treatment is not associated with ele-
vated risk of abnormalities in the timing of secondary dentition in this
patient group. We recommend, however, regular dental evaluations of
pediatric OI patients regardless of the medication because of the fre-
quent dental aberrations associated with OI.
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